These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3837819)

  • 21. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal osteodystrophy: alpha-Heremans Schmid glycoprotein/fetuin-A, matrix GLA protein serum levels, and bone histomorphometry.
    Coen G; Ballanti P; Balducci A; Grandi F; Manni M; Mantella D; Pierantozzi A; Ruggeri M; Sardella D; Sorbo G; Bonucci E
    Am J Kidney Dis; 2006 Jul; 48(1):106-13. PubMed ID: 16797392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence that different vitamin D sterols have qualitatively different effects in man.
    Rasmussen H; Bordier P
    Contrib Nephrol; 1980; 18():184-91. PubMed ID: 7353375
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term experience of alfacalcidol in renal osteodystrophy.
    Sharman VL; Brownjohn AM; Goodwin FJ; Hately W; Manning RM; O'Riordan JH; Papapoulos SE; Marsh FP
    Q J Med; 1982; 51(203):271-8. PubMed ID: 7146311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1,25-dihydroxycholecalciferol in patients with chronic renal failure.
    Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG
    Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654
    [No Abstract]   [Full Text] [Related]  

  • 26. [Management of renal osteopathy in patients with chronic dialysis].
    Kiss D; Brunner FP
    Schweiz Med Wochenschr; 1996 Oct; 126(42):1792-8. PubMed ID: 8966512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcium metabolism in renal failure.
    David DS
    Am J Med; 1975 Jan; 58(1):48-56. PubMed ID: 1090150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 29. Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial.
    Hiramatsu R; Ubara Y; Sawa N; Hoshino J; Hasegawa E; Kawada M; Imafuku A; Sumida K; Mise K; Hayami N; Suwabe T; Takaichi K
    Am J Kidney Dis; 2015 Jul; 66(1):175-7. PubMed ID: 25979349
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of I,25-dihydroxycholecalciferol in renal osteodystrophy.
    Silverberg DS; Bettcher KB; Dossetor JB; Overton TR; Holick MF; DeLuca HF
    Can Med Assoc J; 1975 Jan; 112(2):190, 193-5. PubMed ID: 1111876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal osteodystrophy: past and future.
    Slatopolsky E; Lopez-Hilker S; Dusso A; Brown A; Delmez J; Martin K
    Contrib Nephrol; 1990; 78():38-45; discussion 45-6. PubMed ID: 2225842
    [No Abstract]   [Full Text] [Related]  

  • 32. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH.
    Coen G; Ballanti P; Bonucci E; Calabria S; Costantini S; Ferrannini M; Giustini M; Giordano R; Nicolai G; Manni M; Sardella D; Taggi F
    Nephron; 2002 May; 91(1):103-11. PubMed ID: 12021526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin D today.
    DeLuca HF
    Dis Mon; 1975 Mar; ():1-37. PubMed ID: 165923
    [No Abstract]   [Full Text] [Related]  

  • 34. [Use of "active" vitamin D in uremic osteodystrophy].
    Tarchini R; Mioli V; Baldelli S; Figus S; Pacchiarotti P
    Minerva Med; 1982 Oct; 73(40):2775-8. PubMed ID: 6290945
    [No Abstract]   [Full Text] [Related]  

  • 35. Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed.
    Ferreira MA
    Nephrol Dial Transplant; 2000; 15 Suppl 5():8-14. PubMed ID: 11073268
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effects of 1-alpha-hydroxyvitamin D 3 treatment of osteodystrophy in uremic patients treated with periodic hemodialysis].
    Palmieri P; Albertazzi A; Cappelli P; Di Paolo B
    G Clin Med; 1981 Jul; 62(7):443-60. PubMed ID: 7308629
    [No Abstract]   [Full Text] [Related]  

  • 37. Skeletal abnormalities in chronic renal insufficiency before and during maintenance hemodialysis.
    Ritz E; Krempien B; Mehls O; Malluche H
    Kidney Int; 1973 Aug; 4(2):116-27. PubMed ID: 4790866
    [No Abstract]   [Full Text] [Related]  

  • 38. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF
    Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
    [No Abstract]   [Full Text] [Related]  

  • 39. The pathogenesis of renal osteodystrophy: role of vitamin D, aluminium, parathyroid hormone, calcium and phosphorus.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Johnson JR; George CR; Collett P; Kalowski S
    Q J Med; 1985 May; 55(217):127-44. PubMed ID: 4001311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole-body in-vivo neutron activation analysis in assessing treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Naik RB; Gosling P; Price CP; Robinson BH; Dabek JT; Heath DA; James HM; Kanis JA; Smith R
    Br Med J; 1976 Jul; 2(6027):79-83. PubMed ID: 1276820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.